Influenza (seasonal)

Protection Without a Vaccine

Last month, a team of scientists announced what could prove to be an enormous step forward in the fight against H.I.V.
Scientists at Scripps Research Institute said they had developed an artificial antibody that, once in the blood, grabbed hold of the virus and inactivated it. The molecule can eliminate H.I.V. from infected monkeys and protect them from future infections.

WHO recommends annual vaccination to combat swine flu

Annual vaccination is the most effective solution for combating seasonal influenza infections such as swine flu, which has killed more than 1,200 people this year in India, the World Health Organisation has said.
"It is recommended that people get a flu vaccine even during seasons when drifted viruses are circulating. It's because vaccination can prevent some infections and can reduce serious ailments that can lead to hospitalisation and death," stated the Geneva-based agency.

VaxInnate, BARDA extend contract to develop influenza vaccines

The Biomedical Advanced Research and Development Authority (BARDA), a branch of the U.S. Department of Health and Human Services, recently extended its contract with VaxInnate Corporation for the development of the VAX2012Q influenza vaccine.
The contract, which was originally drafted in February 2011, will now be extended through February 2016. It was revised after the government completed a review of VaxInnate’s development of VAX2012Q, a seasonal influenza vaccine candidate, as well as vaccines for pandemic influenza.

MediVector finishes enrolling subjects in two Phase 3 favipiravir studies

MediVector, Inc. recently announced that it has finished enrolling subjects in its two FAVOR favipiravir Phase 3 studies for influenza treatments.
Favipiravir, also called T-705, is an orally administered antiviral candidate with a broad-spectrum of treatments. The treatment inhibits RNA messengers and genomes from producing the proteins that are essential to forming new viruses.

Investigators advance a new therapy to use against pneumonia, influenza

Scientists at the Nanyang Technological University in Singapore say they've completed a successful mouse study of a new antibody designed to spur the recovery of patients suffering from pneumonia and influenza. And they're now preparing for human studies.
NTU Singapore's Associate Professor Andrew Tan led an interdisciplinary team of scientists to test the antibody, which blocks the protein ANGPTL4, found in high concentrations in tissue from flu and pneumonia patients.

Pandemic immune response hints at potential universal flu vaccine

The search for a universal flu vaccine has focused on the stem of the lollipop-shaped hemagglutinin of the influenza virus. While the composition of the head changes, the stem is fairly constant from strain to strain. New data shows the body takes advantage of this fact too.

Development Of Universal Flu Vaccine Is On The Horizon

With the new type of antibodies capable of counteracting different strains of influenza A viruses, universal flu vaccines may be developed.  Based on a new research at McMaster University and the Icahn School of Medicine at Mount Sinai, New York, this vaccine is different from the current seasonal vaccines that are frequently reformulated because of high mutation rates of flu viruses.  People just need to take a single annual shot of this new vaccine to protect themselves from all serotypes of flu viruses, including the strains that undergo constant mutation.  

La grippe particulièrement sévère cette année

Une forte activité de la grippe saisonnière est enregistrée en ce mois de janvier avec des cas de décès dans certaines localités. Parmi ces victimes figurent des enfants, une femme enceinte et des personnes âgées, soit les personnes à risque de complication et pour lesquelles la vaccination contre la grippe est recommandée.

Study: Boosted flu vaccine benefits elderly in care facilities

A study published Thursday finds that the Fluzone High-Dose vaccine, which contains four times more antigens than the regular vaccine, benefits elderly recipients who live in long-term care facilities.
The University of Pittsburgh School of Medicine recently completed the first study of high-dose vaccines for elderly in care facilities.

Study finds flu virus, vaccine effect closely tied

A Swiss study released Thursday said how much protection the flu shot provides depends on how closely the vaccine matches the circulating virus.
Adrian Egli and colleagues from the University of Basel began with blood samples from organ-transplant patients, as these individuals are at an increased risk for acquiring infections because their immune systems are riddled by immune-suppressive drugs used to prevent rejection. Under these circumstances, vaccines fail to work well.